David Luke Fischer, M.D., Ph.D.

Affiliations: 
2006-2010 Radiology, Neurology Michigan State University, East Lansing, MI 
 2010-2018 Translational Science and Molecular Medicine Michigan State University, East Lansing, MI 
 2018- Neurology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Parkinson's disease, deep brain stimulation, brain-derived neurotrophic factor
Google:
"D. Luke Fischer"
Bio:

D. Luke Fischer is a neuroscientist specializing in Parkinson's disease research. He graduated Phi Beta Kappa from Michigan State University with degrees in Philosophy and Biochemistry & Molecular Biology, and he remained there to complete his PhD in Neuroscience in the laboratory of Dr. Caryl E. Sortwell as part of a dual-MD/PhD program. As a trainee in the NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research at Michigan State University, his focus was on the use of deep brain stimulation in rodent models of Parkinson's disease to investigate its potential as a neuroprotective therapy. He remained in her laboratory as a postdoctoral fellow to examine the impact of common genetic variants on clinical outcomes for developing precision medicine approaches for treating patients with Parkinson's disease. Luke is currently in the neurology residency program at the University of Alabama at Birmingham.

Mean distance: 18.69 (cluster 19)
 
SNBCP

Parents

Sign in to add mentor
Kevin L. Berger research assistant 2007-2010 Michigan State
Andrea Cathryn Bozoki research assistant 2007-2010 Michigan State
Caryl E. Sortwell grad student 2010-2015 Michigan State
Caryl E. Sortwell post-doc 2015-2016 Michigan State

Collaborators

Sign in to add collaborator
Timothy  J. Collier collaborator 2010-2018 Michigan State
Jack W. Lipton collaborator 2011-2018 Michigan State
Fredric P. Manfredsson collaborator 2012-2018 Michigan State
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Fischer DL, Sortwell CE. (2018) BDNF provides many routes toward STN DBS-mediated disease modification. Movement Disorders : Official Journal of the Movement Disorder Society
Duffy MF, Collier TJ, Patterson JR, et al. (2018) Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease. Frontiers in Neuroscience. 12: 621
Duffy MF, Collier TJ, Patterson JR, et al. (2018) Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation. 15: 169
Fischer DL, Auinger P, Goudreau JL, et al. (2018) Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. Parkinsonism & Related Disorders
Duffy MF, Collier TJ, Patterson JR, et al. (2018) Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation. 15: 129
Fischer DL, Manfredsson FP, Kemp CJ, et al. (2017) Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression. Scientific Reports. 7: 16356
Fischer DL, Manfredsson FP, Sortwell CE. (2017) Can STN DBS protect both nigral somata and innervation of the striatum? Annals of Neurology
Fischer DL, Kemp CJ, Cole-Strauss A, et al. (2017) Subthalamic Nucleus Deep Brain Stimulation Employs TrkB Signaling for Neuroprotection and Functional Restoration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience
Su X, Fischer DL, Li X, et al. (2017) Alpha-Synuclein mRNA Is Not Increased. Molecular Therapy : the Journal of the American Society of Gene Therapy
Polinski NK, Manfredsson FP, Benskey MJ, et al. (2016) Impact of age and vector construct on striatal and nigral transgene expression. Molecular Therapy. Methods & Clinical Development. 3: 16082
See more...